Article
Medicine, General & Internal
Laida Elberdin, Rosa M. Fernandez-Torres, Maria Mateos, Maria Outeda, Eva Blanco, Maria I. Gomez-Besteiro, Isabel Martin-Herranz, Eduardo Fonseca
Summary: This study found a positive correlation between ustekinumab concentration and clinical response in psoriatic patients, suggesting ustekinumab concentration could be used to predict treatment efficacy. The presence of anti-ustekinumab antibodies may serve as a potential cause for treatment failure.
FRONTIERS IN MEDICINE
(2022)
Review
Medicine, General & Internal
Sophie Restellini, Waqqas Afif
Summary: The aim of TDM is to optimize the treatment of IBD patients with biologic agents, particularly newer agents like ustekinumab and vedolizumab. The use of TDM with these newer agents is still in its infancy, and the clinical utility of TDM with non-anti-TNF mechanisms of action remains unclear. This review summarizes the latest pharmacokinetic data on newer biologics and oral small molecules, emphasizing the threshold concentrations associated with improved outcomes in IBD patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Infectious Diseases
Christophe Marti, Pierre Lescuyer, David Tonoli, Elodie von Dach, Angela Huttner
Summary: Therapeutic drug monitoring (TDM) of amoxicillin is important for overcoming antimicrobial resistance. This study aimed to define target amoxicillin plasma concentrations and assess their association with clinical outcomes. Results showed significant variations in amoxicillin concentrations, but low trough levels did not correlate with clinical failure. Although no toxicity threshold was established, patients with the highest trough concentrations did not experience increased adverse events, suggesting that trough levels up to 40 mg/L may be safe.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Gastroenterology & Hepatology
Claire Liefferinckx, Antoine Hubert, Debby Thomas, Jeremie Bottieau, Charlotte Minsart, Anneline Cremer, Leila Amininejad, Francois Vallee, Jean-Francois Toubeau, Denis Franchimont
Summary: This study aims to evaluate the impact of Ustekinumab (UST) pharmacokinetics (PK) in Crohn's disease (CD) patients and find predictive markers of UST response. The results show a relationship between early UST drug concentrations and clinical and endoscopic outcomes.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Immunology
Xiaoyuan Li, Ying Tan, Feng Yu, Minghui Zhao
Summary: The proportion of successfully withdrawn from glucocorticoids (GC) in lupus nephritis patients is low, and it requires a long duration and meticulous monitoring. There is no risk of relapse after GC withdrawal.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Yushan Pan, Waseem Ahmed, Prerna Mahtani, Rochelle Wong, Randy Longman, Dana Jeremy Lukin, Ellen J. Scherl, Robert Battat
Summary: Data on therapeutic drug monitoring in postoperative Crohn's disease are limited. This study found that higher concentrations of tumor necrosis factor antagonists were associated with improved outcomes, while ustekinumab concentrations did not show a relationship with outcomes.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Psychiatry
Sara Baldelli, Stefania Cheli, Cristina Montrasio, Dario Cattaneo, Emilio Clementi
Summary: This study analyzed data from the past 5 years to evaluate the application of AGNP guidelines in the clinical management of psychiatric patients. The results showed a significant interpatient variability in drug concentrations and a potential benefit of therapeutic drug monitoring and pharmacogenetic testing in optimizing treatment for individual patients with psychiatric disorders.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
(2021)
Article
Rheumatology
Serdal Ugurlu, Bilgesu Ergezen, Bugra Han Egeli, Oguzhan Selvi, Huri Ozdogan
Summary: Anakinra has been proven effective for colchicine-resistant patients with FMF by reducing attack frequency and subclinical inflammation. The study showed a significant decrease in attack frequency and disease severity in patients receiving anakinra treatment, with 71 patients still on treatment and 32% discontinuing due to insufficient response or side effects.
Article
Rheumatology
Nadil Zeiadin, Emmanouil Rampakakis, Eric Turcotte, Helena Senta, John S. Sampalis, Carter Thorne
Summary: The study examined the safety and efficacy of Y-90 synovectomy in patients with refractory synovitis, showing sustained benefits at 12 months and providing preliminary evidence supporting its clinical efficacy. This research suggests that Y-90 radiosynoviorthesis is a safe alternative to surgical synovectomy in cases of refractory synovitis, marking the first study of its kind in a Canadian cohort.
Review
Medicine, General & Internal
Camilla de Almeida Martins, Karoline Soares Garcia, Natalia Sousa Freita Queiroz
Summary: This review assesses the role of therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD), focusing on its implementation in different scenarios. TDM can help optimize the use of immunobiologics in the treatment of IBD patients, and is of great significance in clinical practice.
FRONTIERS IN MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Waqqas Afif, Bernie Sattin, Dorota Dajnowiec, Reena Khanna, Cynthia H. Seow, Martin Williamson, Kinda Karra, Yanli Wang, Long-long Gao, Brian Bressler
Summary: In consecutive CD patients treated with UST, the addition of TDM into routine clinical practice did not significantly impact clinical decisions and there was no association between short-term clinical outcomes and serum [UST]. Further studies are warranted before clinicians routinely implement UST TDM into clinical practice.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Merve Sivridas, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Romkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens, Luc J. J. Derijks
Summary: The aim of this study was to determine the association between vedolizumab (VDZ) trough concentration and clinical and biochemical remission in the maintenance phase. The results showed no statistically significant correlation between VDZ concentration and clinical remission in all patient groups. However, patients in biochemical remission had higher VDZ trough concentrations. Therefore, there is an association between VDZ concentration and biochemical remission, but not with clinical remission.
Article
Multidisciplinary Sciences
Masaichi Kato, Ken Sugimoto, Kentaro Ikeya, Ryosuke Takano, Ai Matsuura, Takahiro Miyazu, Natsuki Ishida, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Hiroyuki Hanai
Summary: This study investigated the correlation between ADA monitoring and real-world IBD clinical outcomes, finding that ADA continuity was associated with AAA positivity and serum ADA levels. Significant differences were observed between endoscopic remission and non-remission groups based on serum ADA levels.
Review
Gastroenterology & Hepatology
Nilesh Lodhia, Shanti Rao
Summary: This review summarizes the latest data on therapeutic drug monitoring (TDM) in patients with inflammatory bowel disease on biologics and/or immunomodulators, discussing reactive and proactive TDM approaches to manage patients who do not respond well to these medications.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Chemistry, Medicinal
Changhee Ha, Hyun-Seung Lee, Eun Yeon Joo, Young-Min Shon, Seung Bong Hong, Dae-Won Seo, Soo-Youn Lee
Summary: The study investigated the therapeutic drug monitoring of Levetiracetam in Korean epilepsy patients, revealing a large inter-individual difference in its pharmacokinetics and its susceptibility to EIAEDs. There was a strong correlation between weight-adjusted Levetiracetam dosage and concentrations.
